SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-128997
Filing Date
2020-04-30
Accepted
2020-04-30 17:25:39
Documents
12
Period of Report
2020-04-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d894922d8k.htm   iXBRL 8-K 25665
  Complete submission text file 0001193125-20-128997.txt   148467

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atra-20200429.xsd EX-101.SCH 3068
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20200429_lab.xml EX-101.LAB 18137
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20200429_pre.xml EX-101.PRE 11406
11 EXTRACTED XBRL INSTANCE DOCUMENT d894922d8k_htm.xml XML 3376
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 20836933
SIC: 2836 Biological Products, (No Diagnostic Substances)